Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@genomics-online.com

Human MYRIP CRISPR gRNA + Cas9 in Lenti Particles

This is a Myosin VIIA and Rab Interacting Protein plasmid with gRNA + Cas9 insert cloned into Lentiviral VectorpLenti-U6-sgRNA-SFFV-Cas9-2A-Puro. Insert length: not_set. Stable, Transient expression. Suitable for PExp and GEEN. Bacterial selection: Ampicillin.
Catalog No. ABIN5207962
$857.21
Plus shipping costs $50.00, if applicable $20.00 dry ice
300 μL
Shipping to: United States
Delivery in 31 to 41 Business Days

Quick Overview for Human MYRIP CRISPR gRNA + Cas9 in Lenti Particles (ABIN5207962)

Gene

MYRIP (Myosin VIIA and Rab Interacting Protein (MYRIP))

Application

Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)

Insert

gRNA + Cas9

Vector

Lentiviral Vector

Vector Backbone

pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro

Promoter

U6 Promoter, SFFV Promoter

Bacterial Resistance

Ampicillin

Expression Type

Stable, Transient
  • Species

    Human

    Purpose

    Individual gRNA against MYRIP in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)

    Sequence

    Sequence available upon placing order

    Specificity

    GRNAs are designed for use with Cas9 Nuclease only.
    Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells.

    Components

    Lentiviral particles with an individual gRNA (300 μL) for a specific sequence of MYRIP

    Selectable Marker

    Puromycin

    Sequencing Primer

    U6 Forward Primer: 5'--TACGTCCAAGGTCGGGCAGGAAGA--3'
  • Application Notes

    Recommended for quality control: Restriction Enzyme Digest and Sequencing

    Restrictions

    For Research Use only
  • Format

    Viral Particles

    Storage

    -80 °C

    Expiry Date

    12 months
  • Target

    MYRIP (Myosin VIIA and Rab Interacting Protein (MYRIP))

    Alternative Name

    MYRIP

    NCBI Accession

    NM_015460
You are here: